mAbs

Molecular engineering and design of therapeutic antibodies

(2008) Leonard G Presta   CURRENT OPINION IN IMMUNOLOGY

Considerations for the development of therapeutic monoclonal antibodies

(2008) Patrick G Swann et al.   CURRENT OPINION IN IMMUNOLOGY

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti‐CD20 × anti‐CD3), mediates efficient killing of B‐cell lymphoma cells even with very low CD20 expression levels

(2008) Michael Stanglmaier et al.   INTERNATIONAL JOURNAL OF CANCER

Antibody-drug conjugates ace the tolerability test

(2008) Nitin K Damle   NATURE BIOTECHNOLOGY

Weighing the outcomes

(2008) Michael J Russo et al.   NATURE BIOTECHNOLOGY

Trouble at the office

(2008) Malorye Allison   NATURE BIOTECHNOLOGY

Toward biosimilar monoclonal antibodies

(2008) Christian K Schneider et al.   NATURE BIOTECHNOLOGY

Tier 4 Drugs and the Fraying of the Social Compact

(2008) Thomas H. Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commentary: Practicing on the Tip of an Information Iceberg? Evidence of Underpublication of Registered Clinical Trials in Oncology

(2008) S. Ramsey et al.   ONCOLOGIST

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE

Upstream processes in antibody production: Evaluation of critical parameters

(2007) Era Jain et al.   BIOTECHNOLOGY ADVANCES